In vitro, asciminib synergizes with ponatinib to induce growth arrest and apoptosis in CML cells harboring BCR::ABL1 T315I alone or in a compound constellation [11]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.